Literature DB >> 18459520

Alefacept for erosive lichen planus: a case series.

Anne Lynn S Chang1, Joanna Badger, Wingfield Rehmus, Alexa Boer Kimball.   

Abstract

INTRODUCTION: Erosive mucosal lichen planus is thought to be an autoimmune disease mediated by increased T-cell activation and proliferation. Alefacept is a biologic agent that selectively targets memory T cells.
OBJECTIVE: To evaluate the preliminary efficacy and safety of alefacept in the treatment of moderate to severe mucosal LP.
METHODS: Seven subjects were randomly selected to receive either alefacept 15 mg or placebo every week for 12 weeks. Endpoints of the case series were the Physician Global Assessment (PGA) of disease severity, mucosal pain (MP) severity, and itch severity (IS). Both subjects and investigators were blinded.
RESULTS: Two of the subjects receiving alefacept achieved significant improvement during the study. There were no serious adverse events during the course of the study period.
CONCLUSIONS: In this small case series, alefacept may have conferred a modest therapeutic response in erosive lichen planus (LP). Larger multicenter prospective studies will be needed to determine whether alefacept can improve erosive LP in a statistically significant way.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18459520

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  Interventions for treating oral lichen planus: corticosteroid therapies.

Authors:  Giovanni Lodi; Maddalena Manfredi; Valeria Mercadante; Ruth Murphy; Marco Carrozzo
Journal:  Cochrane Database Syst Rev       Date:  2020-02-28

Review 2.  Therapeutic strategies for oral lichen planus: State of the art and new insights.

Authors:  Dario Didona; Raffaele Dante Caposiena Caro; Antonio Manuel Sequeira Santos; Farzan Solimani; Michael Hertl
Journal:  Front Med (Lausanne)       Date:  2022-10-04

3.  Biologics in dermatologic therapy - an update.

Authors:  Arijit Coondoo
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.